Brief Report
Volume: 36 | Issue: 1 | Published: Mar 31, 2020 | Pages: 8 - 9 | DOI: 10.24911/BioMedica/5-142
Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030
Authors: Mehwish Khan
Article Info
Authors
Mehwish Khan
Department of Mass Communication, University of Karachi, Karachi
Publication History
Received: December 28, 2019
Revised: February 16, 2020
Accepted: March 14, 2020
Published: March 31, 2020
Abstract
N/A
Keywords: Hepatitis B. Cost of Fighting
Pubmed Style
Mehwish Khan. Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. BioMedica. 2020; 31 (March 2020): 8-9. doi:10.24911/BioMedica/5-142
Web Style
Mehwish Khan. Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. https://biomedicapk.com/articles/142 [Access: December 22, 2024]. doi:10.24911/BioMedica/5-142
AMA (American Medical Association) Style
Mehwish Khan. Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. BioMedica. 2020; 31 (March 2020): 8-9. doi:10.24911/BioMedica/5-142
Vancouver/ICMJE Style
Mehwish Khan. Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. BioMedica. (2020), [cited December 22, 2024]; 31 (March 2020): 8-9. doi:10.24911/BioMedica/5-142
Harvard Style
Mehwish Khan (2020) Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. BioMedica, 31 (March 2020): 8-9. doi:10.24911/BioMedica/5-142
Chicago Style
Mehwish Khan. "Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030." 31 (2020), 8-9. doi:10.24911/BioMedica/5-142
MLA (The Modern Language Association) Style
Mehwish Khan. "Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030." 31.March 2020 (2020), 8-9. Print. doi:10.24911/BioMedica/5-142
APA (American Psychological Association) Style
Mehwish Khan (2020) Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. , 31 (March 2020), 8-9. doi:10.24911/BioMedica/5-142